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Abstract
Background: Specific isoniazid (INH) resistance conferring mutations have been shown to impact the likelihood of
tuberculosis (TB) transmission. However, their role in the clinical presentation and outcomes of TB has not been evaluated.
Methods: We included all cases of culture-confirmed, INH monoresistant tuberculosis reported to the San Francisco
Department of Public Health Tuberculosis Control Section from October 1992 through October 2005. For cases with stored
culture isolates, we used polymerase chain reaction (PCR) testing and gene sequencing to identify INH resistance-conferring
mutations, and compared genotypic and phenotypic characteristics.
Results: Among 101 consecutive cases of INH monoresistant TB in San Francisco 19 (19%) had isolates with a katG mutation
other than S315T; 38 (38%) had isolates with the katG S315T mutation, 29 (29%) had isolates with a inhA-15;c-t promoter
mutation, and 15 (15%) had isolates with other mutations. The katG S315T mutation was independently associated with
high-level INH resistance (risk ratio [RR] 1.56, 95% confidence interval [CI] 1.07–2.27), and the inhA-15;c-t promoter mutation
was inversely associated with high-level INH resistance (RR 0.43, 95% CI 0.21–0.89). However, specific INH resistance-
conferring mutations were not associated with the clinical severity or outcomes of INH monoresistant TB cases.
Conclusion: These data suggest that INH resistance-conferring mutations do not impact the clinical presentation of TB.
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Introduction
Resistance to first-line anti-tuberculosis (TB) medications is a
continuing global health problem [1]. In particular, resistance to
isoniazid (INH) is very common, with a prevalence of 10% among
new cases and 28% among previously treated cases reported
globally in 2009 [2]. Resistance to INH in Mycobacterium tuberculosis
is mediated by at least two genes, katG [3] and inhA [4]. Mutations
in other genes such as ahpC have been evaluated previously, and
are considered compensatory mutations [5] that may be a marker
for INH resistance, but do not appear to confer INH resistance
[6]. Prior studies have shown that clinical outcomes are similar in
patients with fully drug susceptible and INH monoresistant TB
[7], and suggest that specific INH resistance-conferring mutations
impact the transmissibility and pathogenicity of M. tuberculosis [8]
[9]. Specifically, strains with the katG S315T mutation were
associated with increased transmission and pathogenicity (mea-
sured by the proportion of cases that were considered as part of a
chain of transmission) compared to INH-resistant strains with
other mutations.
Because specific INH resistance-conferring mutations affect the
ability of a strain to cause secondary cases, we hypothesized that
they may also affect the host response and outcomes of infection.
To test this hypothesis, we evaluated the genotypic and phenotypic
characteristics of a well-characterized cohort of INH monoresis-
tant TB cases in San Francisco.
Methods
Ethics statement
This study was approved by the University of California, San
Francisco Human Research Protection Program. The requirement
for informed consent was waived because this was a retrospective
study and posed minimal risks to human subjects.
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As previously described [7], we retrospectively abstracted data
on demographic and clinical characteristics, treatment, and
clinical outcomes for all cases of de novo INH monoresistant TB
reported in San Francisco, California between October 1992 and
November 2005. We excluded cases from this analysis if culture
isolates were unavailable, known INH resistance-conferring genes
were not successfully amplified, or the phenotypic level of INH-
resistance was not known. In addition, we included only the first
case from any group of clustered cases. Cases were considered to
be clustered if their isolates demonstrated the same restriction
fragment length polymorphism (RFLP) genotype based on the
IS6110 marker, the same drug resistance profile, the same drug
resistance-conferring mutation, and belonged to the same M.
tuberculosis lineage, as previously described [8]. Results presented
below were not significantly different when all cases in a cluster
were included in the analysis.
Lineage
The three predominant phylogenetic lineages of M. tuberculosis in
San Francisco are the East-Asian lineage, the Euro-American
lineage, and the Indo-Oceanic lineage [10]. Multiplex real-time
PCR was used to amplify lineage-specific markers [10,11,12], and
each lineage was defined based on previously described methods
[8].
Drug resistance associated mutations
We identified INH resistance-conferring mutations from M.
tuberculosis culture isolates stored at 280 degrees Celsius. Briefly,
for all isolates with phenotypic resistance to INH we performed
real time polymerase chain reaction (PCR) to identify the katG
S315T mutation and the -c15t inhA promoter mutation [8]. Next,
for isolates without either of these two mutations, we sequenced
the inhA promoter region and the entire furA-katG locus to identify
other mutations [8]. The resulting mutations were sorted into four
previously described groupings [8]: Group 1: isolates with a katG
mutation other than S315T, Group 2: isolates with a katG S315T
mutation, Group 3: isolates with a inhA-15;c-t promoter mutation,
and Group 4: isolates with other or no identified mutations. We
did not include mutations in ahpC because these do not appear to
confer INH resistance [6].
Definitions
Drug susceptibility was confirmed in all cases using the agar-
proportion method. INH resistance was classified as either low-
level or high-level when there was .1% growth of M. tuberculosis
complex in the presence of 0.2 ug/mL or 1 ug/mL of INH,
respectively. Clinical characteristics, including presenting symp-
toms, the presence or absence of cavitation on chest radiographs,
and treatment outcomes were abstracted from the San Francisco
Department of Public Health Tuberculosis Clinic electronic
database and charts. Treatment was considered completed if all
anti-tuberculosis chemotherapy had been administered and there
was either microbiological confirmation of cure or an indication in
the medical record that the patient had received an effective
course of treatment. An adverse drug reaction was defined as any
symptom or laboratory abnormality leading to interruption of $1
anti-tuberculosis medication. Treatment outcomes of interest
included death on TB treatment, culture positivity 2 months after
treatment initiation, and treatment failure or relapse. In accor-
dance with ATS/CDC/IDSA guidelines, a patient was considered
to have treatment failure if culture results remained positive after 4
months of treatment and to have had a relapse when a second
episode of tuberculosis was diagnosed within one year after
treatment completion.
Statistical methods
We performed bivariate analysis using the chi-squared test or
Fisher’s exact test for categorical variables and Mann-Whitney
rank-sum test for continuous variables. We performed logistic
regression to measure the association between INH resistance-
conferring mutation groups and lineage. We performed multivar-
iate analysis using a Poisson regression model with robust error
variance [13] to determine the association between INH
resistance-conferring mutation group and high-level INH resis-
tance. To account for potential confounding, we decided a priori to
adjust for the following pre-specified variables: age, gender,
foreign-born status, HIV serostatus, prior active TB treatment,
and prior latent tuberculosis infection (LTBI) treatment. We
evaluated trends in INH monoresistant TB cases by using Poisson
regression, as previously described [14]. We performed all analyses
in Stata 10.0 (Stata Corporation, College Station, TX).
Results
Study population
Of 137 TB cases with INH monoresistance identified during the
study period, 36 were excluded from the analysis (25 isolates were
not available, 2 isolates did not have sufficient DNA to analyze, 6
isolates had unknown INH resistance level (low vs. high), and 3
Table 1. Demographic and Clinical Characteristics.
Characteristic N (%)
Male 61 (60)
Age, median years (IQR) 43 (29–65) years
Ethnicity
Non-Hispanic white 7 (7)
Non-Hispanic black 4 (4)
Hispanic 10 (10)
Asian/Pacific Islander 79 (78)
Native American 1 (1)
Foreign-born 89 (88)
Homeless or single room occupancy hotel resident 9 (9)
History of drug abuse 8 (8)
History of alcohol abuse 12 (12)
HIV-infected 5 (5)
Prior active tuberculosis treatment 20 (20)
Prior latent tuberculosis treatment 19 (19)
Pulmonary tuberculosis 90 (89)
Positive AFB smear test 48 (47)
Fever 28 (28)
Night sweats 26 (26)
Weight-loss 33 (33)
Cough 50 (50)
Hemoptysis 16 (16)
Cavitary chest radiograph 16 (16)
High-level isoniazid resistance 63 (62)
Abbreviations:
AFB: Acid Fast Bacilli.
IQR: Interquartile Range.
doi:10.1371/journal.pone.0037956.t001
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characteristics of the study population are shown in Table 1. Of
101 cases included in the analysis, 90 (89%) were pulmonary and
48 (47%) were sputum smear-positive. The median age of the
study population was 43 years, 60% were male, 88% were foreign
born, and 5% were HIV co-infected. In addition, 20 (20%) had
prior treatment for active TB, and 19 (19%) had prior treatment
for LTBI. High-level INH resistance was present in 63 (62%)
cases. Demographic and clinical characteristics were similar
between cases with high and low-level INH resistance, and
between cases that were and were not included in the analysis
(p.0.05 for all comparisons).
Drug-resistance alleles
A katG mutation other than S315T was found in 19 isolates
(Group 1); 38 isolates had the katG S315T mutation (Group 2), 29
isolates had a inhA-15;c-t promoter mutation (Group 3), and 15
isolates had other (8) or no identified (7) mutations (Group 4). No
isolates had more than one mutation. There was no significant
change in the proportion of cases caused by isolates in Groups 2
(p=0.16), 3 (p=0.19), and 4 (p=0.68) during the 13-year study
period (Figure 1). The proportion of isolates with Group 1
mutations decreased significantly during the first four years of the
study (p=0.005), but there was no significant change thereafter.
Figure 1. Isoniazid (INH) resistance-conferring mutations from 1992–2005 in San Francisco. Each line represents the number of cases in
each INH resistance mutation group over time. The proportion of cases caused by isolates with group 1 mutations decreased significantly over the
first four years of the study (p=0.005), but there was no significant trend thereafter.
doi:10.1371/journal.pone.0037956.g001
Table 2. Association between Three M. tuberculosis Strain Lineages and Isoniazid-Resistance Conferring Mutations.
East-Asian
Lineage Euro-American Indo-Oceanic
Other
lineages Odds Ratio P-value
Mutation, n (%) (n=17) (n=44) (n=36) (n=4) (95% CI)
a
(1) katG other than S315T 6 (35.3) 8 (18.2) 5 (13.9) 0 (0) 2.98 (0.94–9.48) 0.064
(2) katG S315T 4 (23.5) 18 (40.9) 14 (38.9) 2 (50.0) 1.28 (0.57–2.88) 0.55
(3) inhA-15;c-t promoter 4 (23.5) 9 (20.5) 14 (38.9) 2 (50.0) 2.12 (0.88–5.14) 0.096
(4) Other or none identified 3 (17.6) 9 (20.5) 3 (8.3) 0 (0) 2.19 (0.71–6.69) 0.171
aFor each lineage, logistic regression was used to compare the proportion of the most frequent mutation to its proportion in the other lineages combined.
doi:10.1371/journal.pone.0037956.t002
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Of the 101 strains of M. tuberculosis, 17 (17%) belonged to the
East-Asian lineage, 44 (44%) to the Euro-American lineage, 36
(36%) to the Indo-Oceanic lineage, and 4 (4%) to other lineages.
Clinical presentation was not significantly different among these
lineages (Table S1). A high proportion of cases of East-Asian
lineage had katG mutation other than S315T (Group 1) (35.3%),
and a high proportion of cases of Euro-American lineage had katG
S315T mutations (Group 2) (40.9%). However, there were no
significant associations between specific INH resistance-conferring
mutations and genetic lineage (Table 2).
Bivariate and Multivariate Analyses
In bivariate analysis (Table 3), there was no significant
association between INH resistance- conferring mutation group
and clinical presentation of TB (including cough, hemoptysis,
fever, night sweats, weight-loss, and cavitary chest radiograph;
p.0.05 for all comparisons). Demographic characteristics were
similar across all INH resistance-conferring mutation groups
(p.0.05) (Table 3). There were only three adverse clinical
outcomes – one relapse after successful treatment (Group 2
mutation), one treatment failure resulting in death (Group 3
mutation), and one death during treatment (Group 2 mutation).
However, the proportion of isolates with high-level INH resistance
varied among different mutation groups, with 63% of Group 1,
92% of Group 2, 24% of Group 3, and 60% of Group 4 isolates
exhibiting high-level INH resistance. When compared to isolates
with Group 1 mutations, isolates with Group 2 mutations were
more likely to have high-level INH resistance (92% vs. 63%,
p=0.04) and isolates with Group 3 mutations were less likely to
have high-level INH resistance (24% vs. 63%, p=0.01). After
adjustment for age, gender, foreign-born status, HIV, and prior
active or latent TB treatment (Table 4), Group 2 mutations
remained associated with high-level INH resistance (risk ratio
[RR] 1.56, 95% confidence interval [CI] 1.07–2.27, P=0.02), and
Group 3 mutations remained inversely associated with high-level
INH resistance (RR 0.43, 95% CI 0.21–0.89, P=0.02).
Discussion
This study describes a large cohort of INH monoresistant TB
cases, and is the only study of which we are aware to correlate
specific INH resistance-conferring mutations with the clinical
presentation and outcome of TB. We found that INH resistance-
conferring mutations were associated with differing levels of
phenotypic INH resistance. However, specific mutations did not
impact the clinical presentation of TB, and there were few adverse
outcomes across all mutation groups.
Our data are consistent with previous studies demonstrating an
association between the katG S315T mutation and high-level INH
resistance. katG encodes a mycobacterial catalase-peroxidase that
also activates INH from its prodrug state, likely to an INH-
nicotinamide adenine dinucleotide (NADH) adduct [15]. Muta-
tions of the native serine residue at katG position 315 can alter the
enzyme’s ability to bind INH. An enzymatic kinetic study
demonstrated that the katG S315T mutation was among the least
active mutations in producing the INH-NADH adduct among 23
katG mutants tested [16]. Thus, MTB strains with the katG S315T
mutations may activate less INH than other katG mutants, and
therefore survive under higher concentrations of INH. However,
our data suggest specific INH resistance-conferring mutations do
not impact other clinical manifestations of TB.
Table 3. Clinical Presentation Characteristics of Isoniazid (INH) Mono-Resistant Tuberculosis Cases by INH Resistance Group.
INH Resistance Group (%)
Group 1 Group 2 Group 3 Group 4 P-value
Characteristic, n (%) (n=19) (n=38) (n=29) (n=15)
Fever 9 (47) 9 (23) 7 (24) 3 (20) 0.62
Night Sweats 10 (52) 8 (21) 6 (21) 2 (13) 0.17
Weight-loss 8 (17) 13 (34) 8 (28) 4 (27) 0.97
Cough 13 (68) 18 (47) 13 (44) 6 (40) 0.83
Hemoptysis 6 (32) 7 (18) 3 (10) 0 (0) 0.16
Cavitary Chest Radiograph 4 (21) 7 (18) 3 (10) 2 (13) 0.80
doi:10.1371/journal.pone.0037956.t003
Table 4. Association Between Isoniazid (INH) Resistance-conferring Mutations and High-Level INH Resistance.
Mutation Group Total Cases High-Level INH Resistance
Association with High-Level INH
Resistance P-value
n (%) Adjusted Risk Ratio (95% CI)
a
(1) katG other than S315T 19 12 (63) reference
(2) katG S315T 38 35 (92) 1.56 (1.07–2.27) 0.02
(3) inhA-15;c-t promoter 29 7 (24) 0.43 (0.21–0.89) 0.02
(4) Other or none identified 15 9 (60) 1.01 (0.62–1.64) 0.98
aPoisson regression with robust error variance was used to measure association between INH resistance-conferring mutation group and high-level INH resistance.
doi:10.1371/journal.pone.0037956.t004
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resistance-conferring mutation and genetic lineage, particularly
between the katG mutation other than S315T and the East-Asian
lineage, and between the inhA-15;c-t promoter mutation and Indo-
Oceanic lineage [8]. While our study suggested an association
between the katG mutation other than S315T and the East-Asian
lineage, these results did not reach statistical significance.
There are several potential reasons for the lack of an association
between INH resistance mutation group and clinical presentation
of TB. First, it is possible that strains harboring the katG S315T
mutation are more resistant to INH and more easily transmissible,
but are no more virulent in humans than strains harboring other
INH resistance-conferring mutations. This contrasts with murine
studies showing increased virulence of strains with katG S315T
mutation [17]. Second, host factors may be more important than
pathogen-related factors in determining clinical manifestations of
disease. For example, HIV infection and other immunocompro-
mising conditions are associated with more severe disease and
worse clinical outcomes [18] [19] [20]. Lastly, although our data
are from one of the largest population-based series of INH
monoresistance cases, our study may have been underpowered to
detect a difference in clinical outcomes. The vast majority of
patients with INH monoresistant TB had satisfactory treatment
outcomes in our setting. Similar studies in either larger populations
or populations with higher morbidity or mortality could reveal
subtle differences in outcomes between TB cases resulting from
different INH resistance-conferring mutations.
In conclusion, in our population-based sample of INH
monoresistant TB cases, we confirmed the previously reported
association between the katG S315T mutation and high-level INH
resistance, and an association between inhA promoter mutations
and low-level INH resistance. No mutation was associated with
differing clinical manifestations of TB, and adverse outcomes were
uncommon across all mutation groups. Our data suggest that INH
resistance-conferring mutations may not impact the clinical
presentation of M. tuberculosis and that routine genetic testing of
INH monoresistant isolates is unlikely to have diagnostic or
prognostic value. However, further studies are needed to
determine whether specific INH resistance-conferring mutations
impact clinical presentation or outcomes in the setting of HIV-co
infection or multiple drug resistance.
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